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Freek W.A. Verheugt, MDSEE PAGE 111T he fact that blood coagulation plays a role inthe pathogenesis of acute vascular diseasehas resulted in a large number of clinical
trials on the effectiveness of antiplatelet drugs,
including aspirin, in cardiovascular disease (CVD)
(1). Acute myocardial infarction (MI) is generally asso-
ciated with partial or complete thrombotic occlusion
of 1 of the coronary arteries. Both ﬁbrin and platelets
are involved in the formation of thrombi. Because
recently formed thrombi are mainly composed of
ﬁbrin and aggregated platelets, vasoactive mediators
such as thromboxane A2 released from platelets may
occlude coronary vessels. It has therefore been sug-
gested that antiplatelet drugs may be active in the
primary prevention of MI. Indeed, in a retrospective
study involving 473 patients treated with aspirin for
rheumatoid arthritis, the drug seemed to reduce the
incidence of MI, angina pectoris, sudden death, and
cerebral infarction (2). Therefore, antiplatelet therapy
looks attractive in the primary prevention of CVD.
BENEFIT AND RISK OF ASPIRIN IN THE
PRIMARY PREVENTION OF ACUTE MI
The efﬁcacy and safety of aspirin in the primary
prevention of MI have been studied in 6 large-scale
trials including a total 660,000 person-years in
>95,000 subjects, as noted in a collaborative meta-
analysis (3) and put into perspective in a recent re-
view (4). Major coronary events (coronary heart*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Onze Lieve Vrouwe Gasthuis (OLVG), Radboud University,
Nijmegen Medical Centre, Amsterdam, the Netherlands. Dr. Verheugt has
received educational and research grants and honoraria for consultancies/
presentations from Bayer Healthcare.disease mortality and nonfatal MI) are reduced by
18% with aspirin but at the cost of an increase of
54% in major extracranial bleeding. For every 2
major coronary events shown to be prevented by
prophylactic aspirin, they occur at the cost of 1
major extracranial bleed (3). Primary prevention with
aspirin is widely applied, however. This regimen is
used not only because of its cardioprotection but
also because there is increasing evidence of chemo-
protection of aspirin against cancer (5).In this issue of the Journal, Hira et al. (6) present
the results of a prospective study from the National
Cardiovascular Disease Registry’s Practice Innova-
tion and Clinical Excellence registry on the inappro-
priate use of aspirin in primary prevention in nearly
69,000 patients from 119 practices in the United
States. The use of aspirin was considered appro-
priate when the CVD risk was $6% in 10 years
and inappropriate when <6%. More than 10% of pa-
tients received aspirin inappropriately, but there
was a large variability between practices. Interest-
ingly, the patients receiving aspirin inappropriately
were 16 years younger than those with appropriate
use. Inappropriate use decreased over time, from
15% in 2008 to 9% in 2013. The authors concluded
that patients often receive inappropriate aspirin
protection for primary prevention and that their
ﬁndings provide opportunities to improve evidence-
based aspirin use for primary prevention.
The study was performed in cardiology practices,
in which >70% of the records were missing $1
component of the Framingham risk score (6). Because
the evidence of aspirin’s beneﬁt came from other
practices, the results may be biased in that the pop-
ulation seen by cardiologists usually differs from
those in general practice.
TABLE 1 Clinical Setting of 6 Major Randomized Controlled
Trials of Aspirin in the Primary Prevention of CVD
Study (Ref. #) Clinical Setting
British Male Doctor
Study (7)
5,139 male U.K. physicians invited from the
medical directory
Physicians’ Health
Study (8)
22,071 male AMA-registered physicians in the
United States invited by letter
Thrombosis
Prevention
Trial (9)
5,499 high-risk male subjects in 108 general
group practices in the United Kingdom
HOT (10) 18,790 male and female hypertensive patients
in hypertension clinics worldwide
Primary Prevention
Project (11)
4,495 male and female subjects in general
practices in Italy
Women’s Health
Study (12)
39,876 female health professionals in the
United States
AMA ¼ American Medical Association; CVD ¼ cardiovascular disease;
HOT ¼ Hypertension Optimal Treatment.
TABLE 2 5-Year Beneﬁt and Harm of Aspirin in the Primary
Prevention of Vascular Disease
5-Yr
Risk of
CVD*
Beneﬁt
per
1,000
Beneﬁt
per 1,000
With Other
Prevention†
Harm
per
1,000‡
Net
Beneﬁt
per
1,000§
Net Beneﬁt
per 1,000
With Other
Prevention
Low <5% 2 1 1 1 None
Medium 5%–10% 14 8 4 10 4
High >10% 20 10 10 10 None
*CVD includes cardiovascular death, myocardial infarction, or stroke. †Theoretical
situation in which risk is halved by use of statins and other primary prevention
measures. ‡Nonfatal gastrointestinal or extracranial bleeding. §Beneﬁt minus
harm. Adapted with permission from Baigent et al. (3).
Other abbreviation as in Table 1.
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123CLINICAL SETTING OF
PRIMARY PREVENTION WITH ASPIRIN
The majority of clinical trials that have assessed pri-
mary prevention with aspirin were conducted in
general practice (i.e., in hypertension clinics) (Table 1)
(7–12). They did not come from daily cardiology clinic
practice. This makes the work of Hira et al. (6) unique
and important. Cardiologists mainly see patients
with symptomatic heart disease, who are beyond
primary prevention, but there may be patients with-
out coronary disease who see a cardiologist for other
reasons, such as atypical chest pain, arrhythmia, or
heart failure and who are at risk for coronary events.
Thus, there is a clear role for the practicing cardi-
ologists in that risk factors should be collected
and appropriate prophylactic therapy instituted.
However, the basis for the evidence does not initially
come from cardiologists.
CONFOUNDING WITH OTHER
PREVENTIVE STRATEGIES?
When primary prevention with aspirin is applied,
other strategies should be implied as well. There is
overwhelming evidence that CVD can be prevented
by the use of statins. Although there has never been a
randomized trial performed in which the beneﬁt of
aspirin relative to statins has been evaluated, it is
likely that both are effective given their different
modes of action. In fact, observations from random-
ized trials of statins suggest that these agentspotentiate each other (13). Because the bleeding risk
of aspirin is strongly related to the ischemic risk, the
beneﬁt of aspirin may be overshadowed by the
bleeding hazard. Even worse, if aspirin is combined
with other strategies that halve the risk of a major
ischemic event (e.g., as with statins), aspirin’s beneﬁt
is almost completed eliminated (theoretically)
(Table 2), as shown in the meta-analysis discussed
earlier (3). In addition, because the cost of statins has
dropped dramatically over the years (14), the combi-
nation of aspirin with statins has become popular in
primary prevention. Therefore, the baseline risk we
calculated for the eligibility of aspirin may have
changed. In addition to the aforementioned incom-
pleteness of the records, this is another aspect in
which the results of the study by Hira et al. (6) may be
less applicable in current practice.
Aspirin is effective in the primary prevention of
CVD and likely also in cardiology practice. It is asso-
ciated, however, with excess extracranial bleeding
that, regardless of the baseline risk, seems to come
close to its beneﬁt. This limitation of aspirin may be
due to other preventive strategies currently applied
and used extensively in cardiology practice. Thus,
inappropriate use of aspirin should be avoided,
especially in the younger patient population, as
demonstrated in the present study (6).
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Freek W.A. Verheugt, Onze Lieve Vrouwe Gasthuis
(OLVG), Radboud University, Nijmegen Medical
Centre, P.C. Hooftstraat 188, 1071 CH Amsterdam, the
Netherlands. E-mail: f.w.a.verheugt@olvg.nl.RE F E RENCE S1. Antithrombotic Trialists’ Collaboration.
Collaborative meta-analysis of randomised
trials of antiplatelet therapy forprevention of death, myocardial infarction, and
stroke in high risk patients. BMJ 2002;324:
71–86.2. Linos A, Worthington JW, O’Fallon W, Fuster V,
Whisnant JP, Kurland LT. Effect of aspirin on
prevention of coronary and cerebrovascular
Verheugt J A C C V O L . 6 5 , N O . 2 , 2 0 1 5
In Primary Prevention, Cardiologists Can Do Better J A N U A R Y 2 0 , 2 0 1 5 : 1 2 2 – 4
124disease in patients with rheumatoid arthritis. Mayo
Clin Proc 1978;53:581–6.
3. Baigent C, Blackwell C, Collins R, et al., for the
Antithrombotic Trialists’ (ATT) Collaboration.
Aspirin in the primary and secondary prevention of
vascular disease: collaborative meta-analysis of
individual participant data from randomised trials.
Lancet 2009;373:1849–60.
4. Halvorsen S, Andreotti F, Ten Berg J, et al.
Aspirin therapy in cardiovascular disease preven-
tion: a position paper of the European Society of
Cardiology Working Group on Thrombosis. J Am
Coll Cardiol 2014;64:319–27.
5. Patrono C. Low-dose aspirin in primary pre-
vention: cardioprotection, chemoprotection, both,
or neither? Eur Heart J 2013;34:3403–11.
6. Hira RS, Kennedy K, Nambi V, et al.
Frequency and practice-level variation in
inappropriate aspirin use for the primary
prevention of cardiovascular disease: insights
from the National Cardiovascular Disease
Registry’s Practice Innovation and ClinicalExcellence Registry. J Am Coll Cardiol 2015;
65:111–21.
7. Peto R, Gray R, Collins R, et al. Randomised
trial of prophylactic daily aspirin in British male
doctors. BMJ 1988;296:313–6.
8. Final report on the aspirin component of
the ongoing Physicians’ Health Study. Steering
Committee of the Physicians’ Health Study
Research Group. N Engl J Med 1989;321:129–35.
9. MRC General Practice Research Framework.
Thrombosis prevention trial: randomised factorial
comparison of low intensity oral anticoagulation
with warfarin and low dose aspirin in the primary
prevention of ischaemic heart disease in high risk
men. Lancet 1998;351:233–41.
10. Hansson L, Zanchetti A, Carruthers SG, et al.
Effects of intensive blood-pressure lowering and
low-dose aspirin in patients with hypertension:
principal results of the Hypertension Optimal
Treatment (HOT) randomised trial. Lancet 1998;
351:1755–62.11. Collaborative Group of the Primary Prevention
Project. Low dose aspirin and vitamin E in people
at cardiovascular risk: a randomised trial in general
practice. Lancet 2001;357:89–95.
12. Ridker PM, Cook NR, Lee IM, et al.
A randomized trial of low-dose aspirin in
the primary prevention of cardiovascular
disease in women. N Engl J Med 2005;352:
1293–304.
13. Hennekens CH, Sacks FM, Tonkin A, et al.
Additive beneﬁts of pravastatin and aspirin to
decrease risks of cardiovascular disease: random-
ized and observational comparisons of secondary
prevention trials and their meta-analyses. Arch
Intern Med 2004;164:40–4.
14. Verheugt FW. Aspirin, the poor man’s statin?
Lancet 1998;351:227–8.
KEY WORDS aspirin, cardiology practice,
cardiovascular disease, primary prevention
